ANTIVIRAL SCREEN FOR RESPIRATORY VIRUSES

呼吸道病毒的抗病毒筛查

• 批准号: 2297151
• 负责人: PHILIP R WYDE
• 金额: $ 10.28万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-09-30 至 1993-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2297151
• 关键词: ANTIVIRAL; SCREEN; RESPIRATORY; VIRUSES

The overall objective of this contract is to provide a resource for preclinical in vitro evaluation of new antiviral agents against respiratory viruses. All compounds will be screened for their cytotoxicity to human HeLa, mouse L929 and Madin Darby canine kidney (MDCK) cells, and for their antiviral activity against a panel of viruses, including influenza A and B viruses, respiratory syncytial virus (RSV), parainfluenza type 3 (Para 3) virus, and adenovirus type 5. In the initial screen for toxicity, inhibition of cell growth in subconfluent monolayers of tissue cells will be used. Primary screening for antiviral activity will utilize plaque reduction and inhibition of cytopathic effect. Further testing of active compounds will be performed to determine the level of cell toxicity (i.e., DNA, RNA, or protein synthesis inhibition) and the mechanism of antiviral activity (i.e., viral RNA transcription, uncoating). When results warrant, additional studies such as testing the experimental drug in combination with other compounds for toxicity and antiviral efficacy, testing in some detail to determine which step(s) of virus replication are inhibited by the test compound, or testing methods to reduce cell toxicity will be performed.

该合同的总体目的是为 临床前对新抗病毒药物的体外评估 呼吸道病毒。 所有化合物都将筛选 对人类HeLa，Mouse L929和Madin Darby犬的细胞毒性 肾脏（MDCK）细胞及其针对A的抗病毒活性 病毒面板，包括流感和B病毒，呼吸道 合胞病毒（RSV），副粉氟乙烯型（第3段）病毒和 腺病毒5型。在毒性的初始屏幕中，抑制作用 组织细胞的亚综合单层中的细胞生长将是 用过的。 抗病毒活性的主要筛查将利用斑块 减少和抑制细胞质效应。 进一步测试 将执行活性化合物以确定细胞的水平 毒性（即DNA，RNA或蛋白质合成抑制）和 抗病毒活性的机理（即病毒RNA转录， 无涂层）。 当结果需要时，其他研究，例如 与其他化合物结合测试实验药物 为了毒性和抗病毒功效，请详细测试 确定抑制哪个病毒复制步骤 测试化合物或降低细胞毒性的测试方法将是 执行。